This site is intended for Healthcare Professionals only.

CPE raises concern on availability and pricing issues of Atorvastatin tablets

Date:

Share post:

The Community Pharmacy England has raised a concern on pricing and availability of Atorvastatin tablets.

CPE is In discussions with the Department of Health and Social Care (DHSC) and have warned about the serious impact this issue is now having on pharmacies.

The issue was highlighted after a number of pharmacy owners have got in touch with CPE about the pricing and availability of Atorvastatin tablets.

The association said: “The DHSC Supply Team has been working closely with manufacturers and wholesalers on this issue.

Thank you to those of you who have taken the time to report the increased prices that you have purchased at.

We will continue to use these reports to highlight just how much of an impact this is having on pharmacies who are desperately trying to get hold of limited stock and having to pay inflated prices for it without any certainty of their final reimbursement prices.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

51% increase in pharmacy closure since last January-April: PM quizzed in the parliament

"There are over 10 and a half Community pharmacies across the country working incredibly hard to serve their...

BMI linked to work absenteeism, NHS expands obesity and type 2 diabetes programme

Wider rollout of NHS soup and shake diet to help 10,000+ with type 2 diabetes and obesity A recent...

GPhC appoints Louise Edwards as new Chief Strategy Officer

Louise will succeed Mark Voce who is taking early retirement from the GPhC’s position in July 2024 The General...

Community pharmacy patient safety group appoints new leadership

The new CPPSG's to bolster patient safety as community pharmacy expands services Jackie Giltrow and Jose Moss have been...